Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply
Aliment Pharmacol Ther
.
2022 Mar;55(6):735-736.
doi: 10.1111/apt.16795.
Authors
Silvio Danese
1
,
Barrett G Levesque
2
,
Brian G Feagan
3
,
Alina Jucov
4
,
B R Bhandari
5
6
,
Rish K Pai
7
,
Kristen Taylor Meadows
2
,
Brian J Kirby
2
,
Jean-Marie Bruey
2
,
Allan Olson
2
,
Robin Osterhout
2
,
Courtney Van Biene
2
,
Julia Ford
2
,
Richard Aranda
2
,
Kartik Raghupathi
2
,
William J Sandborn
8
Affiliations
1
IRCCS Ospedale San Raffaele and University Vita-Salute, San Raffaele, Milan, Italy.
2
Gossamer, Bio, Inc., San Diego, California, USA.
3
Alimentiv Inc., London, ON, Canada.
4
ARENSIA Exploratory Medicine GmbH, Düsseldorf, Germany.
5
Nicolae Testemitanu State University of Medicine and Pharmacy, Chișinău, Moldova.
6
Delta Research Partners, Bastrop, Los Angeles, USA.
7
Mayo Clinic, Phoneix, Arizona, USA.
8
University of California San Diego, La Jolla, California, USA.
PMID:
35245951
DOI:
10.1111/apt.16795
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Colitis, Ulcerative* / drug therapy
Humans
Hypoxia / drug therapy